Rapport Therapeutics (NASDAQ:RAPP) Director Steven Paul Buys 35,714 Shares of Company Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Steven Paul bought 35,714 shares of the stock in a transaction dated Thursday, October 22nd. The stock was purchased at an average cost of $27.28 per share, for a total transaction of $974,277.92. Following the acquisition, the director owned 77,380 shares in the company, valued at $2,110,926.40. The trade was a 85.71% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Rapport Therapeutics Trading Up 5.9%

Shares of Rapport Therapeutics stock opened at $26.53 on Friday. The company has a 50-day simple moving average of $39.44 and a 200 day simple moving average of $39.02. Rapport Therapeutics, Inc. has a 12-month low of $23.75 and a 12-month high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, analysts predict that Rapport Therapeutics, Inc. will post -4.09 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RAPP. AlphaCentric Advisors LLC grew its holdings in Rapport Therapeutics by 6.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after acquiring an additional 408 shares during the last quarter. Sterling Capital Management LLC increased its position in Rapport Therapeutics by 597.9% in the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after acquiring an additional 843 shares in the last quarter. KBC Group NV bought a new position in shares of Rapport Therapeutics in the first quarter worth about $30,000. State of Wyoming bought a new position in shares of Rapport Therapeutics in the second quarter worth about $65,000. Finally, Swiss National Bank raised its stake in shares of Rapport Therapeutics by 3.5% in the first quarter. Swiss National Bank now owns 56,500 shares of the company’s stock worth $1,768,000 after acquiring an additional 1,900 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on RAPP. Wall Street Zen cut shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, October 15th. Wells Fargo & Company decreased their price target on Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday. BTIG Research raised their price target on Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Citigroup reiterated an “outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $68.36.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The candidate produced statistically significant placebo-adjusted improvements in YMRS and CGI-BP mania-severity scores. Rapport plans to begin Phase 3 trials, potentially expanding RAP-219’s commercial opportunity beyond epilepsy. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts increased or maintained bullish valuations. JonesTrading raised its target to $82, while BTIG reportedly lifted its target to $89. Raymond James raised its target to $86, and HC Wainwright reaffirmed its Buy rating. The consensus target is approximately $68.36, well above recent trading levels. BTIG price target increase
• Positive Sentiment: Company insiders made substantial open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while four directors purchased an additional 52,594 shares. The combined purchases were worth approximately $1.57 million and may signal management confidence following the clinical update. SEC insider filings
• Neutral Sentiment: RAP-219’s move toward Phase 3 is an important milestone, but investors still face clinical, regulatory, financing, and commercialization uncertainty typical of a clinical-stage biotechnology company.
• Negative Sentiment: The clinical results may have been less decisive than some investors expected. Reports indicated that portions of the data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport also remains unprofitable; its latest quarterly loss exceeded analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. Rapport bipolar data report

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.